DelveInsight’s, “Atopic Dermatitis Pipeline Insight, 2023” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Atopic Dermatitis pipeline landscape. It covers the Atopic Dermatitis pipeline drug profiles, including Atopic Dermatitis clinical trials and nonclinical stage products. It also covers the Atopic Dermatitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Atopic Dermatitis Emerging drugs, the Atopic Dermatitis pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Atopic Dermatitis pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Atopic Dermatitis Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Atopic Dermatitis clinical trials studies, Atopic Dermatitis NDA approvals (if any), and product development activities comprising the technology, Atopic Dermatitis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Atopic Dermatitis Pipeline Report
Request a sample and discover the recent breakthroughs happening in the Atopic Dermatitis Pipeline landscape @ Atopic Dermatitis Pipeline Outlook Report
Atopic Dermatitis Overview
Atopic dermatitis, often referred to as eczema, is a chronic (long-lasting) disease that causes inflammation, redness, and irritation of the skin. It is a common condition that usually begins in childhood; however, anyone can get the disease. Atopic dermatitis is not contagious, so it cannot be spread from person to person. Atopic dermatitis causes the skin to become extremely itchy. Scratching leads to further redness, swelling, cracking, “weeping” clear fluid, crusting, and scaling. In most cases, there are periods of time when the disease is worse, called flares, followed by periods when the skin improves or clears up entirely, called remissions.
Recent Developmental Activities in the Atopic Dermatitis Treatment Landscape
For further information, refer to the detailed Atopic Dermatitis Drugs Launch, Atopic Dermatitis Developmental Activities, and Atopic Dermatitis News, click here for Atopic Dermatitis Ongoing Clinical Trial Analysis
Atopic Dermatitis Emerging Drugs Profiles
Amlitelimab SAR445229 (formerly KY1005) is a human monoclonal antibody that targets OX40L, a key regulator of the immune system. Amlitelimab is designed to rebalance the immune system by blocking inappropriate activation and proliferation of ‘pro-inflammatory’ effector T cells and promoting expansion of ‘anti-inflammatory’ regulatory T cells, without broad suppression of the immune system. It is believed this mechanism-of-action means Amlitelimab could be applicable to a range of autoimmune and inflammatory diseases. In Phase I clinical trial in healthy volunteers, Amlitelimab was able to block T cell-driven skin inflammation while being well tolerated. It is believed the immune-modulating mechanism of Amlitelimab has broad potential therapeutic application in multiple diseases caused by immune dysregulation. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.
BX005, a topical phage cocktail that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In preclinical in vitro studies, BX005 was shown to be active against over 90% of strains of S. aureus isolated from the skin of subjects from U.S. and Europe, including antibiotic resistant strains. Currently, the drug is being developed in the Phase I/II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.
LP 0145, is an anti-inflammatory monoclonal antibody under development for atopic dermatitis. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.
Atopic Dermatitis Pipeline Therapeutics Assessment
There are approx. 100+ key companies which are developing the therapies for Atopic Dermatitis. The companies which have their Atopic Dermatitis drug candidates in the most advanced stage, i.e. Phase II include, LEO Pharma.
Find out more about the Atopic Dermatitis Pipeline Segmentation, Therapeutics Assessment, and Atopic Dermatitis Emerging Drugs @ Atopic Dermatitis Treatment Landscape
Scope of the Atopic Dermatitis Pipeline Report
Dive deep into rich insights for drugs for Atopic Dermatitis Pipeline Companies and Therapies, click here @ Atopic Dermatitis Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Atopic Dermatitis Mergers and acquisitions, Atopic Dermatitis Licensing Activities @ Atopic Dermatitis Recent Trends, and Future Perspectives
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/